Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a great year. Shares are up over 50% through the first half of the year on the heels of emerging blockbusters in the diabetes and obesity-care markets.
While sales of Mounjaro and Zepbound are becoming increasingly scrutinized, I’d encourage…
[ad_2]
Source link
